GAEL Q2 FY27: consolidated PAT jumps 247% YoY to ₹131.8 Cr as margins more than double

Gujarat Ambuja Exports' consolidated PAT came in at ₹131.79 Cr for Q2 FY27, up 247% YoY from ₹38.02 Cr a year ago, on revenue of ₹1,450.73 Cr that was down 2.4% YoY. This falls short of our pre-result preview's on-plan range (PAT ₹160–180 Cr, revenue ₹1,550–1,650 Cr, EBITDA margin 14–16%) and is also down 25% QoQ from Q1 FY27's ₹176.77 Cr — so while the YoY story is a genuine margin recovery, not a sequential beat, the quarter undershot the bar set going in. No management guidance exists in our records or in this filing's notes, so there is nothing to grade against on that front beyond the preview. The swing is driven almost entirely by the Maize Processing division, where segment PBIT surged to ₹168.07 Cr from just ₹6.99 Cr a year ago on revenue up 60.5% YoY (₹1,212.26 Cr vs ₹755.45 Cr) — a sharp realization/cost tailwind in starch and sweeteners. That was partly offset by the Other Agro Processing division, where both revenue (₹195.85 Cr vs ₹713.31 Cr, -72.5%) and segment PBIT (₹3.41 Cr vs ₹46.66 Cr) collapsed, which is why total revenue is flat-to-down even as profit more than tripled. Consolidated operating margin (revenue less material/purchase/inventory-change/employee/other opex) rose to 13.60% from 5.10% YoY, and net margin to 9.08% from 2.52% YoY — both roughly doubling or tripling on a low base. Sequentially, though, OPM eased from Q1's 14.55% and NPM from 10.82%, indicating the Q1 momentum moderated rather than accelerated. On corporate activity, the Board also used this meeting to approve the result; the only operationally relevant development in the quarter is the September 9, 2026 announcement of an ₹333 Cr, 850 TPD corn wet milling plant at Hubli, which is additive capacity for the maize franchise but had no bearing on this quarter's print since it is still at the capex stage (consolidated capital work-in-progress rose to ₹633.87 Cr from ₹442.57 Cr at FY26-end). No standalone press release accompanied the filing beyond the board-outcome intimation, so there is no additional management commentary to reconcile against the numbers.